RT Journal Article
SR Electronic
T1 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.02.20088336
DO 10.1101/2020.05.02.20088336
A1 Giacomelli, Andrea
A1 Ridolfo, Anna Lisa
A1 Milazzo, Laura
A1 Oreni, Letizia
A1 Bernacchia, Dario
A1 Siano, Matteo
A1 Bonazzetti, Cecilia
A1 Covizzi, Alice
A1 Schiuma, Marco
A1 Passerini, Matteo
A1 Piscaglia, Marco
A1 Coen, Massimo
A1 Gubertini, Guido
A1 Rizzardini, Giuliano
A1 Cogliati, Chiara
A1 Brambilla, Anna Maria
A1 Colombo, Riccardo
A1 Castelli, Antonio
A1 Rech, Roberto
A1 Riva, Agostino
A1 Torre, Alessandro
A1 Meroni, Luca
A1 Rusconi, Stefano
A1 Antinori, Spinello
A1 Galli, Massimo
YR 2020
UL http://medrxiv.org/content/early/2020/05/06/2020.05.02.20088336.abstract
AB Background Italy was the first European country hit by the COVID-19 pandemic and has the highest number of recorded COVID-19 deaths in Europe.Methods This prospective cohort study of the correlates of the risk of death in COVID-19 patients was conducted at the Infectious Diseases and Intensive Care units of Luigi Sacco Hospital, Milan, Italy. The clinical characteristics of all the COVID-19 patients hospitalised in the early days of the epidemic (21 February -19 March 2020) were recorded upon admission, and the time-dependent probability of death was evaluated using the Kaplan-Meier method (censored as of 20 April 2020). Cox proportional hazard models were used to assess the factors independently associated with the risk of death.Results Forty-eight (20.6%) of the 233 patients followed up for a median of 40 days (interquartile range 33-47) died during the follow-up. Most were males (69.1%) and their median age was 61 years (IQR 50-72). The time-dependent probability of death was 19.7% (95% CI 14.6-24.9%) 30 days after hospital admission. Age (adjusted hazard ratio [aHR] 2.08, 95% CI 1.48-2.92 per ten years more) and obesity (aHR 3.04, 95% CI 1.42-6.49) were independently associated with an increased risk of death, which was also associated with critical disease (aHR 8.26, 95% CI 1.41-48.29), C-reactive protein levels (aHR 1.17, 95% CI 1.02-1.35 per 50 mg/L more) and creatinine kinase levels above 185 U/L (aHR 2.58, 95% CI 1.37-4.87) upon admission.Conclusions Case-fatality rate of patients hospitalized with COVID-19 in the early days of the Italian epidemic was about 20%. Our study adds evidence to the notion that older age, obesity and more advanced illness are factors associated to an increased risk of death among patients hospitalized with COVID-19.Competing Interest StatementAG received consultancy fees from Mylan and non-financial educational support from Gilead. SR received grants, fees for speaker’s bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen. MG received grants, fees for speaker’s bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen and Roche. GR received grants, fees for speaker’s bureau, advisory boards and CME activities from BMS, ViiV, MSD, AbbVie, Gilead, Janssen and Roche. AR received speaker’s honorarium from the following companies Novartis, Sanofi, ViiV, BMS, Gilead, Roche, Merck, MSD. SA received support for research activities from Pfizer and Merck Sharp & Dome. LO, MS, DB, CB, MP, MP, GG, MC, AC, MS, CC, AMB, RC, AC, RR, LM, AT, LM and ALR has nothing to declare.Funding StatementThe study was not funded.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.